Recent studies have shown that hyperglycaemia is related to breast cancer progression; however, the mechanisms underlying the relationship between hyperglycaemia and breast cancer cell survival remain unknown. Here, we demonstrate that as compared to physiological glucose conditions, high glucose conditions promote a significant increase in MCF-7 cell survival under hypoxia. High glucose levels inhibit apoptosis and induce epithelial-tomesenchymal transition, resulting in increased cell viability under hypoxic conditions. Moreover, high glucose-treated cells display significant increases in intracellular Zn 2+ levels and reduction in mRNA expression of the zinc (Zn) transporter Zrt-and Irt-like protein 6 (ZIP6) in hypoxia. ZIP6 deficiency disturbs intracellular Zn 2+ homeostasis, leading to increased cell survival in hypoxia and reduced E-cadherin expression, indicating that decreased ZIP6 expression is strongly associated with resistance to hypoxia.
Breast cancer is the most common malignant tumour in women, and the main risk factors that predispose individuals to developing the disease include genetic anomalies, old age and obesity [1] [2] [3] [4] . Importantly, clinical epidemiological studies have demonstrated that diabetic patients with breast cancer in developed countries are frequently diagnosed with more advanced tumours than nondiabetic patients with breast cancer [5] [6] [7] [8] , and epidemiological studies have also shown that the overall mortality rate of breast cancer is 30-60% higher in patients with diabetes than in patients without diabetes [5-7,9-13]. Moreover, studies have Abbreviations EMT, epithelial-mesenchymal transition; ERa, oestrogen receptor alpha; GSK-3b, glycogen synthase kinase-3; NF-jB, nuclear factor-kappa B; PKC-bII, protein kinase C bII; RT-PCR, reverse transcription-polymerase chain reaction; STAT3, signal transducer and activator of transcription 3; ZIP, Zrt-and Irt-like protein; Zn, zinc.
shown that diabetic patients with breast cancer and nondiabetic patients with breast cancer differ with respect to cancer progression and therapy responsiveness [5,9,14]. The outcomes of previous studies indicate that diabetes is strongly associated with malignant progression and that the current breast cancer therapies may not be appropriate for patients with diabetes. Previous studies aiming to determine the relationship between breast cancer and diabetes have focused on insulin resistance and hyperinsulinaemic states resembling those of diabetes [13, 15, 16] . However, the results of several animal and human studies indicate that insulin treatment has no effect on the risk of breast cancer development in patients with diabetes [17] [18] [19] . Other studies have shown that hyperglycaemia plays a key role in breast cancer progression in patients with diabetes [20] [21] [22] [23] [24] [25] [26] [27] . However, the mechanism underlying malignant progression in diabetic patients with breast cancer is largely unknown [20] [21] [22] [23] [24] [25] [26] . Therefore, studies aiming to understand breast cancer progression in diabetes are necessary to facilitate the development of additional effective cancer therapies.
The breast cancer tumour microenvironment contributes to malignant progression and determines therapy responsiveness, which determines the survival of patients with breast cancer [28, 29] . Hypoxia occurs in internal breast cancer structures as a result of rapid tumour cell growth and has previously been shown to induce epithelial-mesenchymal transition (EMT) in breast cancer cells, thereby facilitating cell survival and malignant progression [30] [31] [32] . Cancer cells use glucose as an energy source to facilitate their survival, growth and proliferation; therefore, it is unsurprising that hyperglycaemia alters breast cancer cell phenotypes, which are also assumed to be affected by hypoxia [23] .
Zinc (Zn), which is essential for many cellular processes, has also been reported to function as an intracellular second messenger to recruit extracellular stimuli and thus determine the final outputs of various physiological pathways [33] [34] [35] [36] [37] . In the rat model of breast cancer, Zn was shown to accumulate in cancerous breast tissues [38] . In contrast, normal breast tissues did not display changes in intracellular Zn levels [38] . It has also been reported that breast tissue and serum Zn levels in patients with breast cancer are higher and lower than breast tissue and serum Zn levels in healthy subjects, respectively [39] [40] [41] [42] . Moreover, in vitro studies have shown that intracellular and A B Fig. 1 . High glucose levels promote MCF-7 cell viability in hypoxia. (A,B) MCF-7 cells were cultured with normal glucose media (5.5 mM), high glucose media (25 mM) or osmotic control media (5.5 mM D-glucose plus 19.5 mM D-mannitol) for 2, 4, 6 and 8 days and then subjected to normoxia or hypoxia for 48 h. The viable cells were observed by microscopy (A) and quantified by MTT assay (B). Images of MCF-7 cells cultured under each experimental condition before being exposed to normoxia or hypoxia for 48 h. Scale bars represent 100 lm. The data are presented as the mean AE SD. ***P < 0.001 versus control (5.5 mM D-glucose concentration) and mannitol (5.5 mM D-glucose plus 19.5 mM D-mannitol) in hypoxia, n = 4-28.
extracellular Zn levels regulate many cellular processes, such as autophagy, cell growth and death, and cell migration, which determine the behaviour and therapy responsiveness of breast cancer [22, [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . Intracellular Zn levels are spatiotemporally regulated mainly by specific Zn transporters and play crucial roles in specific diseases [33, 36, 37] . The Zn transporter Zrt-and Irtlike protein 6 (ZIP6) facilitates the influx of Zn into the cytosol, and the gene encoding the transporter has been shown to be an oestrogen-regulated gene in oestrogen receptor-positive breast cancer [53] and has thus served as a reliable marker of oestrogen receptorpositive (luminal A type) clinical breast disease [54] [55] [56] .
A growing body of evidence from previous clinical reports indicates that ZIP6 expression actively contributes to the biological functions of breast cancer cells [22, 48, 49, [57] [58] [59] [60] and is thus not only a critical factor associated with tumour grade, size and stage but also a poor prognostic factor in patients with breast cancer [43, 54] . In addition, the results of cell experimental and clinical observational studies [54, 57, 59, 60] indicate that the role of ZIP6 may differ between metastatic foci and primary tumours. Thus, elucidating the biochemical roles of Zn and ZIP6 in breast cancer may contribute to improvements in the understanding breast cancer and facilitate the development of accurate diagnostic and effective therapeutic The numbers of cells were determined by MTT assay after the cells were exposed to each experimental condition and then subjected to normoxia or hypoxia for 48 h in the absence or presence of the caspase inhibitor zVAD-fmk. The data are presented as the mean AE SD. **P < 0.01, ***P < 0.001, n = 3-4.
strategies that may be used to combat the disease. Our previous studies identified ZIP6 as one of the molecules that plays an essential functional role in glucose-induced cell migration, suggesting that ZIP6 may be candidate marker for tumour cell metastasis in hyperglycaemia characteristic of diabetes [22] . However, the biological mechanisms underlying the effects of Zn and ZIP6 on breast cancer cell survival in hypoxia, as well as mechanisms that facilitate the acquisition of malignant properties by the cells in question under hypoxic conditions, have not been elucidated. Thus, this study was designed to investigate the physiological effects of high glucose on MCF-7 cell survival in hypoxia and to determine the roles of Zn and ZIP6 in this phenomenon. Here, we demonstrated that cells cultured under high and normal glucose conditions exhibit differences in survival in a hypoxic environment and that these differences are attributable to the effects of Zn and ZIP6. Our results also show that altered Zn and ZIP6 levels in MCF-7 cells exposed to glucose long term contribute to increases in the ability of cells to resist hypoxic environments.
Materials and methods
Standard cell biochemical methods were used for cell culture, hypoxia model, cell viability assay, western blotting, immunostaining, Zn 2+ assay, semiquantitative expression analysis with reverse transcription-polymerase chain reaction (RT-PCR), generation of ZIP6-knockdown MCF-7 cells and statistical analysis. Detailed methods are described in Appendix S1.
A C B Fig. 3 . MCF-7 cells were cultured with high glucose medium to induce EMT under hypoxic conditions. (A,B) MCF-7 cells were cultured with normal glucose media (5.5 mM), high glucose media (25 mM) or osmotic control media (5.5 mM D-glucose plus 19.5 mM D-mannitol) for 8 days, and then subjected to normoxia or hypoxia for 48 h. After 48 h of hypoxic stimulation, the changes in E-cadherin and vimentin protein levels in MCF-7 cells were assayed by western blotting (A), and the ratio of vimentin/E-cadherin protein in MCF-7 cells is shown (B).
(C) E-cadherin expression and dynamic actin remodelling in MCF-7 cells cultured with high glucose medium before being subjected to hypoxia for 48 h. Scale bars represent 50 lm. The data are presented as the mean AE SD. *P < 0.05, ***P < 0.001, n = 3-6.
Results
High glucose levels promote MCF-7 cell survival in hypoxia
To determine the impact of high glucose levels on MCF-7 cell survival in hypoxia, we examined the viability of MCF-7 cells that were cultured under normal physiological glucose conditions (5.5 mM glucose) or hyperglycaemic conditions (25 mM glucose) before being exposed to normoxia or hypoxia for 48 h. Cell death was induced at a significantly higher rate in MCF-7 cells cultured with 5.5 mM glucose or osmotic control medium (5.5 mM glucose with 19.5 mM mannitol) for 8 days before being exposed to hypoxia for 48 h than in cells cultured under the same glucose conditions before being exposed to normoxia for 48 h. In contrast, cell survival was significantly increased in cells cultured with 25 mM glucose for 8 days before being exposed to hypoxia compared to cells cultured with 5.5 mM glucose or osmotic control medium (Fig. 1A) . Figure 1B shows the results of a quantitative analysis of cell viability, which was performed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay in each experimental group. The survival rate of the cells pretreated with 25 mM glucose before being exposed to hypoxia was three-fold higher than that of the cells pretreated with 5.5 mM glucose before being exposed to hypoxia. The rate increased in a time-dependent manner in the former group compared to the latter group (Fig. 1B) . Moreover, we found that MCF-7 cells showed resistance to hypoxiainduced apoptosis when pretreated with medium containing 25 mM glucose ( Fig. 2A) . Pretreating MCF-7 cells with 25 mM glucose significantly decreased the percentage of hypoxia-induced apoptotic nuclei in cells cultured under hypoxic conditions compared to pretreating MCF-7 cells with 5 mM glucose (Fig. 2B ). In addition, hypoxia-induced cell death in MCF-7 cells cultured with 5.5 mM glucose or osmotic control medium was completely suppressed by treatment with 100 lM zVAD-fmk, a general caspase inhibitor (Fig. 2C) . These results indicate that exposure to high glucose mediates cell survival in hypoxia by inducing resistance to hypoxia-induced apoptosis. Recent studies have shown that hypoxia triggers EMT in tumour cells in breast cancer, thereby facilitating cell survival and cancer progression [28] [29] [30] [31] . To gain insight into the mechanisms responsible for the resistance to hypoxia induced by high glucose treatment, we investigated whether MCF-7 cells exposed to high glucose medium undergo EMT. Treatment with 25 mM glucose for 8 days significantly increased the expression of vimentin, a marker for the mesenchymal phenotype (Fig. 3A) , and the ratio of vimentin to E-cadherin, a marker for the epithelial phenotype, by 2.5-fold compared to treatment with 5.5 mM glucose (Fig. 3B) . These findings indicated that high glucose levels induce EMT. E-cadherin expression levels were significantly decreased in 25 mM glucose-treated cells compared to that of 5.5 mM glucose-treated cells after exposure to hypoxia for 48 h (Fig. 3A,C) . Moreover, the vimentin-to-E-cadherin ratio (Fig. 3B) and F-actin expression levels (Fig. 3C) were increased in 25 mM glucose-treated cells compared to 5.5 mM glucose-treated cells, indicating that exposure to high glucose levels maintains EMT under hypoxic conditions.
Zinc and ZIP6 are essential for glucose-induced viability in hypoxia
We next investigated whether Zn 2+ is involved in glucose-induced increases in cell viability under hypoxic conditions, as previous studies have reported that ZIP6-mediated Zn 2+ transport plays an important role in regulating apoptosis and EMT in breast cancer progression [49, [56] [57] [58] . Figure 4 showed the results of monitoring free intracellular Zn 2+ concentration in hypoxia. Before hypoxia, the cells cultured with the different condition displayed similar level of intracellular Zn 2+ . For overtime after a 24-h hypoxic insult, -specific indicator FluoZin-3. The data are presented as the mean AE SD. *P < 0.05, **P < 0.01, n = 3-5.
high glucose-treated cells were found to have significantly increased levels of intracellular labile Zn 2+ ; however, 5.5 mM glucose-and 5.5 mM glucose and 19.5 mM mannitol-treated cells showed little changes in intracellular free Zn levels under hypoxic conditions (Fig. 4) . Moreover, the specific membrane-permeable Zn chelator TPEN significantly inhibited the survival of 25 mM glucose-treated cells for overtime after a 24-h hypoxic insult (Fig. 5A,B) , an inhibition that was rescued by increasing the level of intracellular free Zn 2+ with Zn ionophore pyrithion. These findings suggest that intracellular Zn plays an essential role in high glucose-induced survival in hypoxia.
The mRNA expression of the Zn transporter ZIP6 was downregulated in a hypoxia-dependent manner in 25 mM glucose-treated cells (Fig. 6A,B) . However, treatment with 5.5 mM glucose or 5.5 mM glucose with 19.5 mM mannitol had relatively small effect on ZIP6 mRNA levels in cells exposed to hypoxia compared to 25 mM glucose-treated cells (Fig. 6A,B) . To better understand the roles of ZIP6 and Zn 2+ in high glucose-induced resistance to hypoxia, we generated ZIP6 stable-knockdown MCF-7 cells using shRNA specific for human ZIP6. ZIP6 stable-knockdown cells displayed significantly reduced ZIP6 transcript levels compared to control cells, as demonstrated by RT-PCR analysis (Fig. 7A) . Importantly, ZIP6 knockdown appeared to increase intracellular free Zn 2+ levels (Fig. 7B ) and promote cell survival under hypoxic conditions in the corresponding group compared to the control group (Fig. 7C,  D) . Additionally, ZIP6 stable-knockdown cells showed decreased E-cadherin expression (Fig. 7E) and an increased vimentin-to-E-cadherin ratio compared to control cells, as demonstrated by western blot analysis (Fig. 7F) . These results suggested that ZIP6 gene suppression mediates cell survival under hypoxic conditions following high glucose stimulation by mediating the effects of Zn and regulating EMT. 
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Discussion
In the present study, we provided the first evidence indicating that cell survival under hypoxic conditions was strongly dependent on glucose concentrations and intracellular labile Zn 2+ levels. Zn 2+ plays an essential role in glucose-induced cell survival in hypoxia. Moreover, our findings indicate that ZIP6 is a novel target responsible for glucose-induced increases in cell viability under hypoxic conditions. Previous studies have been shown that MCF-7 cell proliferation in normoxia is not consistently associated with glucose levels; however, high glucose leads to increases in the expression of molecules that are potentially involved in breast cancer progression, such as protein kinase C bII (PKC-bII), glycogen synthase kinase-3 (GSK-3b), nuclear factor-kappa B (NF-jB) and oestrogen receptor alpha (ERa) [20, 21] . We demonstrated that high glucose levels have no influence on MCF-7 cell proliferation in normoxia; however, MCF-7 cell proliferation was significantly enhanced in cells pretreated with high glucose medium and exposed to hypoxia. MCF-7 is a low-invasive early-stage breast cancer cell line that may undergo malignant transformation through the activation of PKC-bII, GSK-3b, NF-jB or ERa under high glucose conditions [20, 21, 56] , resulting to show the phenotypes to rescue from the hypoxic insult. These results highlight the need to consider the effects of the extracellular environment on cell behaviour and indicate that specific therapies may be needed to treat breast cancer influenced by hyperglycaemia.
We found that high glucose-induced cell survival in hypoxia was mediated by the biological actions of Zn 2+ and ZIP6. Intracellular Zn 2+ levels were shown to be a critical regulator of MCF-7 cell survival under hypoxic conditions (Fig. S1 ) and were also found to be required for the promotion of high glucose-induced cell survival. The phenomenon implies that the cells cultured with high glucose are fundamentally reprogrammed in an attempt to try to cope with the hypoxic stress through Zn 2+ , resulting to switch to be able to survival in hypoxia. While on the other hand, the cells cultured with normal media are on edge and cannot prevent by Zn 2+ from hypoxic stress. Our data showed that apoptosis inhibition is an important cause of high glucose-induced cell survival under hypoxic conditions. It has been reported that Zn 2+ exerts cytoprotective effects by which Zn-bound to cysteine residues in the catalytic domain of caspases inhibits their enzymatic activity [61] [62] [63] . It is possible that Zn 2+ is linked to apoptotic signalling and thus confers resistance to hypoxia under high glucose conditions. In MCF-7 cells, the uptake of Zn 2+ into the cytoplasm is dependent on ZIP6 (Table S1 ), whose expression has been reported to be reversed by increases in intracellular Zn 2+ levels [50] , suggesting that ZIP6 plays A B . The data are presented as the mean AE SD. *P < 0.05, ****P < 0.0001, n = 3-4.
important roles in maintaining intracellular Zn 2+ homeostasis. Marked decreases in ZIP6 expression result in disturbances of intracellular Zn 2+ homeostasis, leading to significant increases in intracellular Zn 2+ levels and cell survival as a result of resistance to apoptosis in MCF-7 cells cultured under high glucose conditions and exposed to hypoxia. However, maintenance of normal ZIP6 expression and intracellular Zn 2+ levels results in low cell viability in cells cultured under normal glucose conditions and exposed to hypoxia. It has been reported that ZIP6 knockdown disturbs intracellular Zn 2+ homeostasis, which confers resistance to cell death by apoptosis [50] .
We also demonstrated that ZIP6-knockdown cells failed to maintain intracellular Zn 2+ homeostasis and thus experienced increases in intracellular Zn 2+ levels and survival under hypoxic conditions. It was recently reported that ZIP6 knockdown in adherent T47D human ductal breast epithelial tumour cells causes apoptosis resistance and promotes EMT [58] . Studies have also noted a correlation between ZIP6 and E-cadherin expression in MCF-7 cells, suggesting that tumour aggression is driven by decreases in ZIP6 expression in adherent cells [57] . These data support the findings of previous clinical studies, which noted the existence of a negative correlation between ZIP6 expression and tumour grade, size and stage [43, 54] . Consistent with the findings of previously published reports [58] , we found that EMT induction was accompanied by a decrease in ZIP6 expression in MCF-7 cells exposed to high glucose conditions and that ZIP6 knockdown resulted in an EMT phenotype, a finding supported by our observation of decreases in The changes in E-cadherin and vimentin protein levels in MCF-7 cells transfected with shRNA for ZIP6 or control shRNA were evaluated by western blotting (E), and the ratio of vimentin/E-cadherin protein is shown (F). The data are presented as the mean AE SD. **P < 0.01, ****P < 0.0001, n = 3-12.
E-cadherin expression in the corresponding group of cells. ZIP6 has been recently shown to form a heteromeric complex with ZIP10, resulting to interact with NCAM1 and regulate an EMT paradigm [64, 65] . ZIP6 may require for ZIP10 to control the transporter functions in the process of cell survival during hypoxia, although further studies are needed to clarify the involvement of a ZIP6 and ZIP10 heteromer. Moreover, accumulating evidence indicates that EMT acquisition in hypoxia triggers alternative survival mechanisms by activating a set of genes responsible for facilitating hypoxic responses mediated by HIF-1 and the tyrosine kinase pathway [29] [30] [31] [32] . Our findings suggest that suppressing ZIP6 expression in the presence of high glucose concentrations mediated cell survival by inducing resistance to apoptosis under hypoxic conditions at least in part through EMT; however, additional studies are required to identify the signalling pathway regulated by Zn 2+ . ZIP6 has been shown to play vastly different roles in adherent and nonadherent tumour cells [59] . In a previous work, we demonstrated that Zn 2+ and ZIP6 are required for transient glucose-induced motility [22] , a result consistent with those of a previous study, in which ZIP6 expression was shown to be increased in nonadherent cells and required for the metastatic transformation of MCF-7 cells [59] . Another study showed that high levels of ZIP6 can be found in patients with oestrogen receptor-positive breast cancer with lymph node metastasis [60] . The differences in the effects exerted by high glucose on ZIP6 expression and Zn 2+ between the present study and previous studies were attributed to differences in the glucose treatment durations used in the studies. Transient treatment with glucose may contribute to increases in ZIP6 levels and Zn 2+ uptake to promote motility, while long-term treatment with glucose may decrease ZIP6 expression and disturb intracellular Zn 2+ homeostasis in hypoxia, thereby enabling malignant cells to resist hypoxic stress. However, no changes in cell survival have been noted in normoxia. ZIP6 expression is known to be regulated at the transcriptional level by oestrogen and signal transducer and activator of transcription 3 (STAT3) [33] ; therefore, it is possible that the transcription factors and other molecules responsible for regulating ZIP6 expression are governed by the duration for which they are exposed to glucose. Moreover, it is thought that the extent to which Zn 2+ functions as an intracellular second messenger to transduce extracellular stimuli into intracellular signals varies according to the duration for which cells are treated with glucose. Zn 2+ tightly modulates the quantity of signals transmitted by various types of extracellular stimuli; thus, Zn 2+ plays a critical role in determining the final outputs of signalling pathways [33] [34] [35] [36] .
Breast cancers do not comprise uniform groups of cells. Rather, they comprise complex and heterogeneous aggregations of various types of cells, which are differentially affected by changes in environmental conditions according to the portions of the tumour that they occupy [23, 66] . Thus, researchers have proposed that the selection of effective molecular-targeted therapies for breast cancer can be accomplished by analysing portions of tumours rather than by analysing tumours as a whole. The results of recent reports, including the present study, indicate that sophisticated regulation of ZIP6 plays an important role in the acquisition of a malignant phenotype in response to specific types of stimulation [22, 48, 49, 58, 59] . The results of the analyses of the effects of ZIP6 and Zn 2+ on breast cancer cells under high glucose conditions indicate that agents targeting the above factors may represent effective therapies that can be used to treat breast cancer with diabetes.
In conclusion, our findings show that high glucose levels enhance MCF-7 cell survival under hypoxic stress by disturbing intracellular Zn 2+ homeostasis via decreasing ZIP6 expression. This is the first study to demonstrate that ZIP6 and Zn 2+ are key mediators of breast cancer cell survival under high glucose conditions.
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